Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes
- 22 November 2019
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (5) , 1400-1406
Abstract
Objective To define short-term and long-term outcomes of IORT for the management of BR/LA PDAC in the era of modern neoadjuvant therapy (NAT).Keywords
This publication has 21 references indexed in Scilit:
- Approach to Patients With Pancreatic Cancer Without Detectable MetastasesJournal of Clinical Oncology, 2015
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic CancerAnnals of Surgery, 2015
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Updated long‐term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010Cancer, 2013
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center ExperienceThe Oncologist, 2013
- Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerCancer, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapyCancer, 2007